What is nPODDDS™
nPODDDS™ is Medicap Labs’ proprietary drug delivery platform designed to provide a dual-phase release profile. It delivers an initial loading dose for rapid therapeutic effect, followed by a sustained-release phase that maintains stable drug levels over time.
The platform’s unique Point-of-Divergence (POD) defines the exact transition between the fast-release and controlled-release phases, enabling precise modulation of drug absorption and therapeutic outcomes. This makes nPODDDS™ ideal for drugs where rapid onset and long-lasting effects are both desired.
Why nPODDDS™ Matters
Rapid Onset + Sustained Effect
The technology allows manipulation of multiple variables (polymer type, matrix density, coating parameters), enabling custom release profiles tailored to drug chemistry and therapeutic needs.
Predictable Pharmacokinetics
Suitable for a broad range of pharmaceuticals: from small molecules to more complex APIs — and adaptable for both new drugs (e.g. NDA/505(b)(2) path) and generic controlled‑release products (e.g. ANDA path).
Flexible Across APIs
The flexibility and robustness of Hypermatrix™ can accelerate formulation development and reduce risk, making it well‑suited for tight regulatory timelines and commercial scale‑up.
Regulatory & Commercial Support
Supports both novel drug development (NDA/505(b)(2)) and generic controlled-release products (ANDA).
Typical Use Cases & Therapeutic Areas
nPODDDS™ is particularly useful in scenarios such as:
Fast Relief & Long-Lasting Effect
Drugs that need rapid onset followed by prolonged therapeutic effect (e.g., pain medications).
Simplified Dosing
Formulations requiring once-daily dosing or reduced dosing frequency for improved patient compliance.
Extended-Release Conversion
Conversion of immediate-release formulations into dual-phase or extended-release products.
Precise Therapy Control
Drugs where precise pharmacokinetics are critical for efficacy and patient safety.
At Medicap Labs, we leverage nPODDDS™ to offer:
Formulation Development
Dual-Phase controlled release formulation development: from early-stage concept to commercial ready drug product using the nPODDDS™ platform.
Regulatory Support
Regulatory support for both ANDA (generic) and NDA (505(b)(2) or novel) pathways
Release Customization
Flexible tailoring of release profiles based on API properties and therapeutic targets
Scale-Up
Scale-up and GMP-compliant production capabilities — ensuring reliable transition from lab to commercial batches